Yoğun Bakım Ünitesinde İlaç Kaynaklı Akut Böbrek Yetmezliğinin Önlenmesinde Klinik Eczacının Rolü
Polat, Eyüp Can
Ambargo SüresiAcik erisim
Üst veriTüm öğe kaydını göster
Acute renal failure (ARF) is a disorder that is commonly seen in patients in the intensive care unit (ICU) and has a detrimental impact on the patients' clinical prognosis. Drug-induced ARF is often occurring in the clinic. Today, the clinical pharmacist's consultation service to the healthcare team aids in the resolution of drug-related issues and the enhancement of therapeutic outcomes. Therefore, the aim of this study was to demonstrate the impact of having a clinical pharmacist on the incidence, stages, and treatment of ARF. The study was conducted in ICUs of a university hospital and two patient groups were included: intervention (n=75) (IG) and control (n=75) (CG) groups. The clinical pharmacist visited patients regularly and provided advice to the ICU team on the treatment of IG, and no intervention for CG. ARF was found to be more common in CG than in IG (p<0.05). The difference between the patients' peak serum creatinine and basal serum creatinine values was less in IG (p<0.05). Among the causes of ICU admission, pulmonary edema and acute respiratory failure were found to have a significant and positive relationship with ARF (p<0.05). Furthermore, it was shown that patients with diabetes and cancer comorbidities were the most vulnerable to developing ARF (p<0.05). Antibiotics, anesthetics, and cardiovascular system medication classes were found to have a significant and positive correlation with ARF in patients (p<0.05). Our findings demonstrate that if a clinical pharmacist is included in the ICU team, the incidence of ARF in patients can be minimized and therapeutic outcomes can be improved.